I agree. I can't see what the company could release that would at the least, pause the selling either.
If the only news due is the number of patients enrolled for the trial and which is due around June, why would this be worth holding?
Sponsoring brokers that brought this to market should be asking if blowing up their retail base is a good thing.
EBR news, page-25
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.035(3.00%) |
Mkt cap ! $360.4M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.20 | $1.15 | $162.4K | 138.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7500 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 136024 | 9 |
View Market Depth
| Last trade - 13.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.18 |
Change
0.035 ( 1.72 %) |
||||
| Open | High | Low | Volume | ||
| $1.17 | $1.20 | $1.15 | 52937 | ||
| Last updated 13.29pm 04/06/2024 ? | |||||
| EBR (ASX) Chart |